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Hypothesis: Neuroendocrine Mechanisms
(Hypothalamus–Growth Hormone–STAT5 Axis) Contribute to
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Pulmonary hypertension (PH) is a disease with high morbidity and mortality. The prevalence of idiopathic pulmonary arterial hypertension (IPAH) and hereditary pulmonary arterial hypertension (HPAH) is approximately two- to four-fold higher in women than
in men. Paradoxically, there is an opposite male bias in typical rodent models of PH (chronic hypoxia or monocrotaline); in these
models, administration of estrogenic compounds (for example, estradiol-17β [E2]) is protective. Further complexities are observed
in humans ingesting anorexigens (female bias) and in rodent models, such as after hypoxia plus SU5416/Sugen (little sex bias) or
involving serotonin transporter overexpression or dexfenfluramine administration (female bias). These complexities in sex bias in PH
remain incompletely understood. We recently discovered that conditional deletion of signal transducer and activator of transcription 5a/b (STAT5a/b) in vascular smooth muscle cells abrogated the male bias in PH in hypoxic mice and that late-stage obliterative lesions in patients of both sexes with IPAH and HPAH showed reduced STAT5a/b, reduced Tyr-P-STAT5 and reduced B-cell
lymphoma 6 protein (BCL6). In trying to understand the significance of these observations, we realized that there existed a wellcharacterized E2-sensitive central neuroendocrine mechanism of sex bias, studied over the last 40 years, that, at its peripheral end,
culminated in species-specific male (“pulsatile”) versus female (“more continuous”) temporal patterns of circulating growth hormone (GH) levels leading to male versus female patterned activation of STAT5a/b in peripheral tissues and thus sex-biased expression of hundreds of genes. In this report, we consider the contribution of this neuroendocrine mechanism (hypothalamus-GHSTAT5) in the generation of sex bias in different PH situations.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2015.00122

INTRODUCTION
Pulmonary hypertension (PH) is a disease with high morbidity and mortality,
characterized by pulmonary arterial remodeling with the classic onion-skin
obliterative and plexiform lesions (1–4).
(Some investigators use the phrase “pulmonary arterial hypertension [PAH]” to
generically encompass the human disease
and rodent models. Others use the phrase
“pulmonary hypertension [PH]” as the

generic term and reserve PAH for different forms of the human disease [such as
idiopathic PAH (IPAH) and hereditary
PAH (HPAH)]. In this report, we follow
the second approach.) In IPAH, there is a
sexual dimorphism with the prevalence
approximately two- to four-fold higher in
postpubertal women than in men, with
an earlier onset in women (median age:
third decade in women, fourth decade in
men), but a better outcome after diagno-
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sis in women than in men (1–8). In
HPAH, autosomal-dominant mutations,
mainly in the gene for bone morphogenetic protein receptor 2 (BMPR2), underlie the disease and its female dominance, but with low penetrance (10–15%)
and a delayed onset (1–8). A subset of patients, typically women, taking anorexigens develop PH (9,10). In systemic sclerosis (SSc)-associated PH, SSc is itself
4–10 times more prevalent in women,
thus the occurrence of PH in this disease
is more prevalent in women (11,12).
However, after excluding PH diagnosed
at baseline, male SSc patients have a
higher likelihood of developing PH and a
worse outcome (11,12). Schistosomiasisinduced PH shows no sex bias (13),
whereas HIV-induced PH shows a small
(1.2-fold) male bias (14). The mechanisms
that underlie these sexual dimorphisms
in humans, especially the female bias in
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juxtaposition of a female bias in prevalence of human IPAH and HPAH with a
male bias in disease development in the
chronic hypoxia- or MCT-induced rodent
models, together with the observation
that administration of E2 was protective
in the rodent models, led to the concept
of an “estrogen paradox” to describe
these observations (5,8,15–18). Any hypothesis (Figure 1) that provides a path
toward clarifying these puzzling sex-bias
observations in PH in humans and rodents would be of great value.
Figure 1. Hypothesis: central neuroendocrine and peripheral mechanisms in generation of
sex bias in PH. Male (M: “pulsatile”) versus female (F: “more continuous”) patterned secretion of GH by the pituitary followed by patterned activation of the STAT5a/b-BCL6 axis
represents a well-established pathway (27) to functionally connect the hypothalamus/pituitary on the one hand and pulmonary vascular tissues on the other hand as a mechanism for generating sex-biased gene expression in the latter. Upstream of pituitary/GH
would be multifactorial central sex-bias mechanisms that impinge on the hypothalamus
and effectuate M versus F patterns of secretion of GHRH; these include estradiol-17β (E2),
serotonin (5-HT), cytokines and BMPs. Downstream of STAT5-BCL6 in peripheral pulmonary
vascular cells would be hundreds of responsive genes for which patterned expression together contributes to the sex-biased disease process involving cell proliferation, cell hypertrophy, resistance to apoptosis and cytokine/growth factor secretion. The hypothesis
also includes direct effects of various mediators (for example, cytokines and growth factors) at the level of the peripheral pulmonary vascular cells in a sex- and species-biased
manner due to underlying gene expression changes (of on the order of perhaps
500–1,000 genes) already effectuated through the GH-STAT5 axis.

disease prevalence in IPAH and HPAH,
are incompletely understood (8,15).
There is an opposite male bias in the
typical rodent models of PH induced by
chronic hypoxia or monocrotaline (MCT)
(8,15,16). In these rodent models, estrogenic compounds [(estradiol-17β (E2) and
2-methoxyestradiol (2-ME)] typically inhibit PH (8,15,16). Strikingly, rats or mice
exposed to hypoxia plus the inhibitor
SU5416 (Sugen) develop PH without any
sex bias, and E2 administration has little
protective effect on development of increased right ventricular systolic pressure
in this model (8,17,18). (The phrase “sex
bias” refers to biological and biochemical
differences, and “gender bias” refers to
cognitive, behavioral and cultural differences. Thus, in the present essay, the
phrase “sex bias” is used throughout. The
phrase “sex specific” refers to entities that
are observed exclusively in one or the
other sex [for example, expression of

genes located on the Y chromosome]. In
contrast, the phrase “sex biased” refers to
entities that show a quantitative phenotypic difference between the two sexes.)
In converse examples, female mice overexpressing the serotonin transporter or
the S100 calcium-binding protein
S100A4/mts1, or administered the
anorexigen dexfenfluramine (but not
male mice), spontaneously develop modest PH by 5 months (15,19–22). Although
only up to one-third of male mice expressing the BMPR2R899X transgene spontaneously developed right ventricular
systolic pressure >30 mmHg, this proportion increased to two-thirds when the
mice were fed a high-fat diet (23); in this
model, 2-ME was not protective (24). The
mechanisms underlying these disparate
and contrasting sex-bias observations in
different rodent models, and the differences between rodent models and the
human disease, are not understood. The

A GAP IN KNOWLEDGE IN THE PH
LITERATURE CONCERNING SEX BIAS
MECHANISMS AND EFFECTS OF
EXOGENOUSLY ADMINISTERED E2
We begin by identifying a gap in
knowledge in the PH literature about a
critical aspect of how exogenous E2 injected into an animal “feminizes” gene
expression. We note that all previous
work on sex bias in rodent-based PH
models, including after administration
of steroid sex hormones (for example,
E2, 2-ME or testosterone) and/or gonadectomy, have focused on direct effects of steroid hormones at the level of
peripheral vascular tissues in the lung
(5,6,8,15–26). (However, the terminology
used can often be confusing and, indeed,
misleading. Thus, in the context of a
“neuroendocrine hypothesis,” the term
“central” refers to the hypothalamus and
pituitary [the “neuro-” part], while the
terms “distal” or “peripheral” refer to all
locations in the body where a hormone
can circulate [the “-endocrine” part]).
Thus, there have been extensive studies
of steroid hormone effects (E2, 2-ME,
testosterone) in lung tissues in rodent
models, in isolated human and rodent
pulmonary vascular cells (smooth muscle cells [SMCs] and endothelial cells
[ECs]) and on vascular cell proliferation,
transcriptional regulation of BMPR2
gene expression and BMPR2-initiated
cell signaling (5,6,8,15–26). This exclusive focus on peripheral tissue effects of
steroid hormones is somewhat at odds
with insights gleaned over the last 30–40
years in a sister field (sex-biased expres-
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sion of liver genes) and the mechanism
by which exogenously administered E2
influences this sex bias (27,28). The critical insight from the 1970s has been that
effects of E2 and testosterone on sexbiased gene expression in distal tissues
(liver in this case) depend on the pituitary; hypophysectomy blocks effects of
E2 or testosterone on sex-specific gene
expression (27) (Figure 1). In terms of
vascular biology, it was reported in 1978
(29) and later confirmed in 1992 (30) that
hypophysectomy in the male rat markedly impaired arterial remodeling after
aortic balloon injury, especially vascular
smooth muscle cell proliferation and
myointima formation, but the mechanisms remain undefined.
Overall, the literature in the PH field
today is where the “sex bias in liver gene
expression” field was in the early 1970s.
At that time, the effects of E2 and/or gonadectomy on sex-biased drug metabolism and thus on the sex-biased expression of cytochrome P450 (P450 CYP)
enzymes were thought to be due solely to
direct effects of sex steroid hormones on
the hepatocyte (27,31). However, it was
shown in 1973 by Colby et al. (32), and
extensively confirmed by numerous studies since then (27,33–43), that the feminizing effect on sex-biased liver gene expression of an injection of E2 into a rat or
mouse was indirect and had an absolute
dependence on the pituitary (Figure 1).
As explained in detail by Waxman and
colleagues over the last 2 decades, this
neuroendocrine mechanism of sex bias,
working through an axis consisting of the
hypothalamic arcuate nucleus–growth
hormone releasing hormone
(GHRH)–growth hormone (GH)–signal
transducer and activator of transcription
5 (STAT5) accounts for sex-biased expression of >1,000 genes in the liver and also
of body growth and body weight
(27,41–48) (Figures 2, 3). Parenthetically,
STAT5 is the major transcription factor
activated by the binding of GH to its receptor on all cell types (27,41–48). This
activation involves Tyr phosphorylation
of receptor-associated Janus kinases, with
the latter then mediating Tyr phosphory-

Figure 2. Sex bias in circulating GH patterns in rats and humans (note that the y axes in the
human panels are logarithmic). In rats (panels A and B on left side), male pattern is “pulsatile” with low interpulse levels; female pattern is “more continuous” with higher frequency
of pulses and with GH levels of “non-zero” between pulses. In humans (panels A and B on
the right side), males are pulsatile with low interpulse levels, but in human females, the interpulse levels are high. (Rat data shown are adapted from ref. [62] in compliance with
the terms of usage of the Proceedings of the National Academy of Sciences, USA; human
data shown are adapted from ref. [56] with permission of The Endocrine Society). Additionally, insets in the rat data panels show sex-biased expression of CYP species by Western
blotting, especially the male-specific expression of the 3A subfamily (3A2) (62). For comparison, in mice, M and F pulse heights are similar, the frequency is higher in F and interpulse
levels can be low in both M and F (ref. [55]; not shown).

lation of STAT5. Additional ligand-induced Ser phosphorylation is also observed on STAT5. Thus, much of the biological activity of GH on different cell
types is mediated by this activation of
STAT5. From among the family of STAT
transcription factors, STAT5a and STAT5b
are the only transcription factors that mediate sex bias (27,41–48).
The targets of E2 and testosterone include neuronal cells in the arcuate nucleus and other ventromedial hypothalamic nuclei (49–54) (Figure 4). The
downstream elements of this sex-bias
mechanism are male versus female patterned secretion of GHRH from the hypothalamus into the hypophyseal portal circulation and then corresponding
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patterned secretion of GH by the pituitary
into the general circulation. This finding
was discovered by Edén in 1979 (55) and,
since then, has been extensively confirmed in mice, rats and humans
(27,45–50,56–62). Circulating GH levels in
the male (M) are usually called “pulsatile”
(two to four peaks per day) with very low
interpulse levels; in the female (F), there is
a higher frequency of pulses (seven or
more peaks per day) with significant interpulse levels; thus, this is called “more
continuous” (Figures 1, 2). This scenario
results in M versus F patterned activation
of PY-STAT5a/b in the distal tissues and,
downstream of that, a major cascade of
sex-biased gene expression of >1,000
genes (Figure 3) (27,41–48). Even when as-
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Figure 3. Temporal relationships between the sexually dimorphic spontaneous GH secretory
profiles and hepatic PY-STAT5 activity levels (DNA-binding gel-shift assay) in the normal rat
(adapted from ref. [43] with permission of The Association for the Study of Internal Secretions and The Endocrine Society). Black arrows point to when the liver tissue was harvested
for PY-STAT5 analyses. In males, PY-STAT5 peak heights are higher and interpulse levels very
low (left panels). In females, peak height is lower and interpulse levels higher than in males.

sayed at a single time point in humans (in
the ambulatory state in the morning after
an overnight fast), the median value of
serum GH levels was 80- to 120-fold
higher in women than in men (61). This is
a higher sexual dimorphic ratio than that
for E2 (ratio: 2.2 female bias) or testosterone (ratio: 14 male bias) observed in
the same sera (61). Thus, while the GHSTAT5 axis of sex bias is well documented
in the literature, it seems not to have been
a consideration in the PH literature.
A NOVEL STARTING POINT FOR OUR
STAT5 STUDIES ON SEX BIAS IN PH
For a variety of reasons (28,63,64), we
initiated an investigation into the involvement of STAT5a/b species in the
pathogenesis of PH produced in mice exposed to chronic hypoxia. Mice with heterozygous or homozygous conditional
deletions of the STAT5a/b locus in vascular SMCs were generated in crosses between STAT5a/bfl/fl and transgelin
(SM22α)-Cre+/+ parents (28) (Figure 5).
Wild-type (wt) males subjected to chronic

hypoxia showed significant PH and pulmonary arterial remodeling, with wt females showing minimal changes (a male-

dominant phenotype) (28) (Figure 6).
However, in conditional STAT5–/– mice,
hypoxic females showed the most severe
manifestations of PH (a female-dominant
phenotype) (28) (Figure 6). The reversal
of sex bias in this model of PH did not
require the complete loss of STAT5a/b
genes. Even heterozygous conditional
STAT5a/b+/– mice (thus, with a 50% loss
of STAT5a/b) abrogated the maledominant PH phenotype (28).
Immunofluorescence studies on
human lung sections from patients with
late-stage idiopathic or hereditary pulmonary arterial hypertension (IPAH or
HPAH) showed that SMCs in obliterative
pulmonary arterial lesions, both male
and female, had, overall, reduced
STAT5a/b, reduced PY-STAT5 and reduced B-cell lymphoma 6 protein (BCL6)
(Figure 7), but with interpatient and interlesion variability even in the same patient (28). In concordance with these observations, studies of SMC and EC cell
lines derived from vessels isolated from
lungs of male and female IPAH patients
and controls, revealed instances of coordinate reductions in STAT5a and STAT5b
in IPAH-derived cells, including in SMCs
and ECs from the same patient (28).

Figure 4. Expression of BMPR2 RNA in the mouse brain and includes the arcuate nucleus
of the hypothalamus (white arrows). This image was taken from the atlas, available online
from The Jackson Laboratory. Figure shows result of a cRNA hybridization (adapted from
ref. [78], a PLOS Biology paper).
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Taken together, these data (Figures 5–7)
identified two aspects of STAT5 biology
relevant in the pathogenesis of PH: first,
the contribution of differential male versus female PY-STAT5 activation patterns
in the early stages of this disease to generating the sex bias, and second, the loss of
STAT5 in cells in vascular lesions in many
patients of both sexes in the late stages of
the disease (28). These observations led us
to consider more deeply what was known
about the hypothalamus-GH-STAT5 axis
in determining sex bias in gene expression
and to consider whether those insights
might be applicable to sex bias in PH.
THE HYPOTHALAMIC (GHRH)–PITUITARY
(GH)–DISTAL TISSUES (STAT5, BCL6)
AXIS
Several insights in the prior hypothalamic-GH-STAT5 sex-bias literature are specifically relevant to understanding sex
bias issues in PH. First, how does administration of exogenous E2 (or similar sex
steroid) into an animal produce its effects?
As mentioned earlier, it has been shown
extensively that effects of exogenously injected E2 depend on generating the “feminine plasma growth hormone pattern”
through central hypothalamic/pituitary
mechanisms (27,32–40) (Figure 1). Specifically, a single injection of E2 into a rodent
affects the function of cells in the arcuate
and ventromedial nucleus in the hypothalamus and additional nuclei therein
(27,49–54). These are the very cells that secrete GHRH in male and female patterns
(27). This result then induces the patterned secretion of GH by the pituitary
and then STAT5-driven sex-biased patterns of gene expression in distal tissues
(27,41–48). Critically, that the administration of E2 may work on distal tissues in
terms of sex-bias effects indirectly
through the hypothalamus is an insight
missing from the PH literature (Figure 1).
Second, what is the relevant difference
between a female human and a female
rodent? While, overall, in mice, rats and
humans, males have a “pulsatile” GH
pattern and females have a “more continuous” GH pattern (27), there are quantitative differences in the three species

Figure 5. Immunofluorescence studies using mouse tissues showing selective loss of
STAT5a/b from SMA-positive tunica media (dark arrows: green staining) in main pulmonary artery (PA) (A) or PA segment in a lung section (B) of the conditional STAT5a/b–/–
mice. Quantitation is shown on the right of the respective panels; *P < 0.05. Scale bars =
10 μm. (C) Western blots of extracts of cultured arterial smooth muscle cells derived from
pools of five mice, each of the indicated groups, with SMC-specific conditional homozygous deletion of STAT5a/b verifying the loss of expression of STAT5a (using L-20 pAb from
Santa Cruz Biotechnology), STAT5a + b (using C-17 pAb from Santa Cruz Biotechnology)
and male-biased expression of BCL6. Adapted from ref. (28). pAb, polyclonal antibody.

(Figure 2). In adult male rats, GH is released into the circulation in discrete
pulses approximately every 3.5 h with
little or no circulating GH detectable
during the interpulse interval (62) (Figure 2). In female rats, the pulses are more
frequent, the pulse heights are lower and
the interpulse levels are higher (62) (Figure 2). In mice, the male circulating GH
levels are also pulsatile and with very
low levels through the interpulse intervals (27,38,57). However, in the female
mouse GH levels pulse more frequently
and with the same pulse heights as in the
male mouse, but still with low levels
during the interpulse intervals (27,38,57).
In contrast, men show infrequent GH
pulses of high magnitude, with very low
interpulse levels (Figure 2); however,
women show a more continuous high
level of GH (Figure 2) (39,40,56,59,60).
Thus, a difference between female humans and female rodents is in the much
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higher continuous GH levels in women
compared with female rodents (Figure 2).
Reconstruction experiments in rats show
that exogenous administration of GH in
3-min pulses for up to six pulses per day
generated expression of male-specific
CYP2A2 and 3A2 subfamily genes in the
liver (65). Different aspects of the specific
GH patterns (pulse frequency, pulse
height, interpulse interval and interpulse
levels) affected sex-specific expression of
different CYP enzymes differently, even
in the same species (65–69). In an example specifically relevant to the PH focus
of this essay, these differences included
that the CYP3A subfamily is malespecific in rats, but female-specific in
mice and humans (27,62,65–69). We note
that it is the CYP3A subfamily of enzymes that convert the injected inactive
MCT to the bioactive monocrotaline
pyrrole (MCTP) in male rats that then induces PH (70,71).

REVIEW ARTICLE

Figure 6. Female-dominant PH in homozygous SM22-Cre, STAT5a/b–/– mice after chronic hypoxia. Female homozygous knockout mice developed highest mean right ventricular systolic
pressure (RVSP) measured by Millar catheterization (A), greatest right ventricular hypertrophy
(B) measured by the Fulton index [right ventricle weight/(left ventricle weight + septum
weight)], and greatest PA remodeling (C: wall thickness; D: SMA positive vessels per 10× field;
and E: elastin staining using Verhoeff–van Gieson stain); scale bar = 45 μm. Wt and KO mice
were matched littermates (n = 5/group). *P < 0.05 (adapted from ref. [28]).

Third, the major consequence of the interaction of GH with its receptor at the
cell surface is activation (Tyr phosphorylation) of the STAT5a and STAT5b (“JakSTAT signaling”) (27). Indeed, STAT5 was
identified 2 decades ago as the key transcription factor that mediated the sex-bias
effects of different GH patterns at the
level of distal tissues (27,41–48). Thus, respective M or F patterns of circulating

GH levels are converted into respective
patterned activation of PY-STAT5 in the
liver (Figure 3). This patterned PY-STAT5
activation transcriptionally activated or
repressed >1,000 different genes through
combinations with other preexisting transcription factors (HNF4, C/EBP) as well
as by regulating expression of a master
transcription repressor such as BCL6
(27,41–48). This generates a cascade of

sex-biased gene expression in distal tissues but without the direct effect of any
steroid sex hormone.
In the context of the present PHfocused essay (and the MCT comment
above), it was shown 2 decades ago that
the sex-biased transcriptional expression
of the CYP3A subfamily by GH is mediated by STAT5 (27,72). Moreover, it is
known that hypoxia also activates STAT5
through Tyr phosphorylation (73) and
that STAT5 affects many target genes already shown to be relevant in PH pathogenesis (summarized in Figure 9 in the
article by Yang et al. [28]).
Fourth, the sex-biased expression of
genes is duplicated in isolated human or
rat hepatocytes exposed to the respective
high pulsatile (male) or low, continuous
(female) levels of GH in cell culture
(27,67). Thus, cells isolated from the
body replicate sex-biased gene expression in culture in response to patterns of
GH in the absence of any exposure to sex
hormones.
Fifth, at the molecular level, the patterned activation of PY-STAT5 and downstream cascades of transcription factors
lead to sex-specific expression of target
genes in several categories (27,41–48).
Class I male genes require pulsatile
GH/PY-STAT5 activation, whereas class
II male genes are primarily regulated by
repression by the continuous female pattern of GH. Female class I genes require a
continuous GH/PY-STAT5 activation,
whereas female class II genes are strongly
derepressed (thus upregulated) after hypophysectomy. It is critical to understand
that GH-STAT5–initiated transcriptional
mechanisms that generate sex-biased
changes in expression of hundreds of
genes differently is not a simple on/off
switch in a digital sense. Waxman and
colleagues, and others, have shown in detailed studies (27,41–48) that sex-biased
expression of genes by GH-STAT5 activation in the hepatocyte depends on a “dynamical” signaling process that involves
multiple activation and inactivation cycles (frequency as in “pulsatile” or “continuous”), differences in magnitude of
signal strength (“level” of GH) and the
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rates of these changes (different slopes),
resulting in different rates of association
of different transcription regulatory proteins (including PY-STAT5a/b) at the
level of the chromatin encompassing different genes. It is these differences in signal strength, frequency, slopes of the activation or inactivation reactions, and in
coassociated proteins that lead to different chromatin conformations (active or
inactive for RNA transcription) in the
DNA context of different genes
(27,41–48). The net result is a cellular phenotype driven by the GH-STAT5 axis consisting of a large array (500–1,000) of
genes expressed in a sex-biased manner
differently in different species (Figure 1).
This patterned activation of cells includes longer-lived chromatin remodeling at the respective male- and femalespecific genes in that respective
male-derived hepatocytes were more responsive to the male pulsatile pattern of
GH in culture, and female-derived were
less so (27,67). From this, we anticipate
that this remodeled chromatin will retain
sex-biased phenotype when primary
cells are continued to be maintained in
culture.
Sixth, upstream of the pituitary is the
arcuate nucleus in the hypothalamus,
which secretes GHRH (36,74,75). BMPR1,
BMPR2 and caveolin-1 (cav-1) and various BMPs (-2, -4, -6, -7) are also expressed and function in arcuate neurons
of the hypothalamus (74–78) (Figures 1,
4). Moreover, these are the very neurons
that are the target of exogenously administered E2 converting the GHRH secretion pattern into a feminine continuous
pattern (49–54). Thus, it is necessary to
consider the possibility that pathogenesis
of hereditary PAH might involve contributions of BMPR2 and cav-1 mutations to
changes in signaling and altered intracellular trafficking at the level of neuronal
cell bodies in the arcuate nucleus of the
hypothalamus (Figure 4). This result
would affect patterns of GHRH secretion
and, thus, the neuroendocrine pathway
culminating in STAT5-generated sex-bias
in pulmonary vascular tissues. This neurogenic component has received little at-

Figure 7. Marked reduction of STAT5, PY-STAT5 and BCL6 in cells in obliterative lesions in IPAH
patients. Compiled figure adapted from ref. (28) summarizing data from two studies based
on lung sections provided by the Department of Pathology, The Johns Hopkins School of
Medicine (JHU) and the Pulmonary Hypertension Breakthrough Initiative (PHBI). The top half
of this composite summarizes immunofluorescence data from study 1 showing loss of
STAT5a (red) in SMA-positive (green) cells in obliterative lesions in IPAH. Quantitation of images in (A) is shown in (B) (mean ± standard error of the mean [SE]), and various controls
are shown in (C) and (D). Scale bar = 45 μm. The bottom half of this composite summarizes
study 2 in terms of the quantitation of immunofluorescence data for STAT5a + b, PY-STAT5
and BCL6 (mean ± SE) in obliterative lesions in male and female patients. *P < 0.05.

tention in the PH literature, even though
it is known that chronic hypoxia as well
as intermittent hypoxia decrease plasma
GH levels by effects that include the hypothalamus/pituitary (79,80).
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Seventh, STAT5 is a critical transcription factor in hypothalamic neuronal
cells (74) (Figure 1). Instillation of
granulocyte-macrophage colonystimulating factor (GM-CSF) into the ar-
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cuate nucleus of the hypothalamus activates PY-STAT5 and affects appetite and
thus body fat (74). Nestin-Cre–driven
deletion of STAT5a/b generates mice that
show insulin resistance, put on weight
and become obese, but in a sex-biased
manner; female mice accumulate more
body fat but less lean mass (74). These
Nestin-Cre-STAT5–/– mutant mice no
longer change their food-intake behavior
upon GM-CSF instillation into the hypothalamus (74) (Figure 1). Moreover,
STAT5 and STAT3 also mediate the effects of leptin and the gp130 receptor in
hypothalamic neuronal cells (74,75).
Eighth, the cytokine BMP9 has drawn
recent attention as a “quiescence” promoting factor in vascular biology and in
PH (79,80). Curiously, BMP9 is expressed
largely by the liver, and its promoter region has binding sites for STAT5a/b,
HNF4α and C/EBPα (81,82; Qiagen
CHiP database). BMP9, which is also expressed in the basal forebrain (83), stimulates GH expression (84). Moreover, there
is synergism between BMP9 and GH intracellular signaling pathways in murine
multilineage cells, especially at the level
of the Jak-STAT3 and -STAT5 pathways
(84). Inhibitors of Jak1, STAT3 or STAT5
each inhibited this synergism (84).
SYNTHESIS OF THE LITERATURE ON SEX
BIAS MEDIATED BY THE
NEUROENDOCRINE-GH-STAT5 AXIS
WITH THAT ON SEX BIAS IN PH
The above-enumerated insights involving the neuroendocrine-GH-STAT5
axis allowed us to compile the following
synthesis, potentially explaining many of
the puzzling sex bias–related observations in the PH literature.
First, why is the prevalence of IPAH
higher in women than in men? On average, women have 80- to 120-fold higher
levels of circulating GH than men (61).
Moreover, this is in a more continuous
pattern than in men (Figure 2) (27,56). It is
known that GH promotes vascular
smooth muscle cell proliferation and migration and is required for normal vascular reactivity and modeling (85–88). Indeed, the prevalence of systemic

hypertension is 20–50% in patients with
acromegaly (in whom the plasma GH levels are high) because of “stiffer arteries”
(85,87); no information is available on PH
in acromegaly. We propose that these 80to 120-fold higher levels and a more continuous pattern of GH, and thus activation of different sets of cell cycle, cell proliferation and cell migration regulatory
genes (27), is why IPAH is more prevalent
in women than men. The identification of
molecular targets activated, directly or indirectly, in vascular cells by differences in
male versus female patterns of circulating
GH (and thus PY-STAT5 activation) is unexplored. It is already known that these
gene targets in liver include BMP2, BMP5,
BMP10, Id1, Id2, Id3, BMPER, Smad5 and
Smad7 as female-biased and BMP4 and
BMP6 as male-biased (45–48). We anticipate occurrence of these and also interactions between BMP9 and the GH-STAT5
axis in pulmonary vascular cells (see comments on BMP9 in previous section and
refs. 79–84).
Second, what is the relevant difference
between a female human and a female
rodent underlying differences in sex bias
in PH? There are quantitative differences
in patterns of circulating GH in males
and females in mice, rats and humans resulting in the same gene being regulated
differently in terms of sex specificity in
the three species (Figure 2) (discussed in
detail in refs. 27,56–62,65–69). The major
relevant difference between female humans and female rodents is in the much
higher continuous GH levels in women
compared with female rodents (Figure 2).
Thus, expression of P450 CYP 3A subfamily genes is male-biased in the rat
(62,65), but female-biased in humans
(68). We anticipate that such differences
will underlie sex bias in the development
of PH in the different species.
Third, is there really an estrogen paradox? We suggest that the basis for why
women get more IPAH than men may be
unrelated to E2 levels in women. Importantly, women have an 80- to 120-fold
higher level of GH than men and in a
“more continuous” pattern. This difference far exceeds the 2.2-fold difference in

E2 between women and men or the 14fold difference in testosterone (61). Also,
it has not been appreciated before that E2
may have little to do directly with IPAH
prevalence in women. In animal models,
typically in male rodents, E2 would be
protective by targeting the hypothalamus
directly (49–54). Thus, as has been shown
in the liver literature, E2 would “feminize” GH patterns, changing the male
pattern of expression in rodents to a female pattern (Figure 1). Therefore, the
apparent paradox can be explained by
involving GH in human IPAH and by remembering that E2 directly targets the
hypothalamus, not so much the peripheral vascular tissue.
Fourth, what is the basis for the ghrelin
paradox? Ghrelin is a peptide produced
by, for example, the stomach, which stimulates hypothalamic neurons to secrete
GHRH and thus increase GH secretion
(89). Ghrelin levels are three-fold higher
in women than in men (90). Increased
levels of circulating ghrelin are observed
in IPAH (91). However, paradoxically, in
MCT or hypoxic rat models the administration of ghrelin reduces PH (92,93).
Thus, ghrelin is protective in rodent models but elevated in IPAH. In this instance,
ghrelin has a central effect (stimulates
GHRH and thus GH secretion, as in humans) and a different peripheral effect
(antagonizes endothelin-1) (91).
Fifth, why is the MCT model malebiased in the rat (8,15,16)? Downstream
of the GH/STAT5 axis is the sex-specific
expression P450 CYP3A subfamily members (27,62,65–69). STAT5 is the transcription factor that upregulates CYP3A
(27,72), and it is the CYP3A subfamily
enzymes that metabolize MCT to its active MCTP (70,71). In the rat, this is
male-specific (27,62,66) but is femalespecific in mouse and humans
(27,62,65–69). It should not then be a
surprise that a single injection of MCT
efficiently induces PH in the male rat.
Sixth, why is there no sex bias in the
hypoxia-SU5416 model (8,17,18)? SU5416
(Sugen) has been described in the PH literature as an inhibitor of receptor 2 for vascular endothelial growth factor (VEGF R2) (8).
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However, it has been shown already that
SU5416 inhibits multiple receptor tyrosine kinases (VEGFR, platelet-derived
growth factor receptor [PDGFR], colony
stimulating factor receptor 1 [CSF-1R],
Fms-related tyrosine kinase 3 [Flt3], receptor tyrosine kinase protein [Kit],
proto-oncogene "rearranged during transfection" [Ret], fibroblast growth factor receptor 1 [FGF-R1]) (88). Thus, SU5416 inhibits Flt3-dependent activation of
PY-STAT5 (95). It is also an agonist of the
aryl hydrocarbon receptor (96) and even
inhibits expression and activity of neuronal nitric oxide synthase, thus protecting neurons from apoptosis (97). The
plethora of these effects of SU5416, especially inhibition of PY-STAT5 activation,
suggests why this model does not show a
sex bias. In ovariectomized mice, SU5416
by itself in normoxia produces PH, and
administration of E2 does not affect this
(17). This lack of effect of E2 administration would be the consequence of SU5416
already inhibiting PY-STAT5 activation.
Indeed, in humans, the PY-STAT5 inhibitor dasatinib (98) is known to be accompanied by the occasional development of PH mainly in female patients
(99). As for the differences between rat
and mouse in their response to E2 in the
hypoxia-Sugen model (8,17,18), we note
that it has already been shown that members of the same GH-STAT5–responsive
gene subfamily (for example, the CYP 3A
subfamily) can be male-specific in the rat
and female-specific in the mouse
(27,62,65–69). Thus, we expect that effects
of E2 will indeed be different in the
mouse and the rat given how the GHSTAT5 pathway is already known to
show different sex bias in the regulation
of similar target genes in the two species.
Seventh, why do female mice overexpressing the serotonin transporter or
the S100 calcium-binding protein
S100A4/mts1 or the dexfenfluramineadministered mice, but not male mice, develop modest PH by 5 months (15,19–22)?
Although increased serotonin (5-HT) has
been implicated in the pathogenesis of PH
(10,15,26,100), especially in the femalespecific mouse models developed by

MacLean et al. (19–21), and after administration of an anorectic drug dexfenfluramine (22,100), the mechanistic focus has
largely been on effects of 5-HT on distal
vascular tissues (10,15,19–22,26,100). We
note that it is already known that the PHcausing anorexigens fenfluramine,
aminorex, phentermine and fluoxetine increase 5-HT in the hypothalamus
(101–105) and that fenfluramine blunted
GH responsiveness to GHRH (105). Moreover, estrogens are themselves anorexigenic through effects at the level of the
hypothalamus (106,107) showing that the
central effects of anorexigens can be female-biased. Additionally, it is already
known that PY-STAT5 signaling in the hypothalamus is involved in regulating appetite and sex-biased changes in body
weight (74–77) (Figure 1). Remarkably, it
has been shown already that 5-HT suppresses STAT5 expression and PY-STAT5
activation (108), and 5-HT receptor and
dopaminergic D1 and D2 receptor antagonists also inhibit PY-STAT5 activation (for
example, pimozide) (109,110). Interestingly, the neuroleptic pimozide is now
sold commercially as a low-molecularweight inhibitor of PY-STAT5 activation.
Although Launay et al. (100) reported
that deletion of the serotonin 2B receptor
gene in mice reduced development of
chronic hypoxia-induced increase in right
ventricular systolic pressure and also
blocked its further enhancement by
dexfenfluramine, these investigators used
mice that had a whole-body knockout of
the 5-HTR2B gene (111). These mice had
cardiac defects, and this genetic deletion
would also involve the serotonin system
in the hypothalamus (111). We suggest
that consideration of mechanisms in such
models also include the central effects of
5-HT at the level of the hypothalamus
and sex-specific changes in the patterns
of GH secretion and STAT5 activation.
Eighth, a small subset (3 of 11) of male
mice expressing BMPR2 R899X in smooth
muscle cells developed increased right
ventricular systolic pressure >30 mmHg
(23). However, this was reported as increased to 7 of 11 when these mice were
fed a high-fat diet (23). This result was

696 | SEHGAL ET AL. | MOL MED 21:688-701, 2015

not affected by the estrogen 2-ME (24).
The investigators focused on insulin resistance at the level of peripheral tissues
in this model, but did not consider the
participation of the hypothalamic targets
of a high-fat diet in this pathogenesis.
The hypothalamic mechanisms would
have been apparent from the data of Lee
et al. (74), who showed that NestinCre–driven deletion of STAT5a/b in the
central nervous system (including in the
hypothalamus) led to increased body fat
and increased insulin resistance in mice
in a sexually dimorphic manner. Thus,
central neuroendocrine mechanisms, no
longer responsive to estrogens because of
high-fat diet feeding, should be considered in this model.
Ninth, in primary human pulmonary
artery smooth muscle cells (PASMCs) in
culture (from disease-free individuals),
the expression of BMPR2, Id1 and Id3 but
not Smad1 are higher in male-derived
cells compared with female-derived cells
(25). Thus, these genes show retention of
sex bias in their expression (25). Correspondingly, female-derived PASMCs
proliferate modestly faster in response to
5-HT, PDGF or BMP4 (25). These observations are similar to the findings of
Thangavel et al. (67), who observed that
GH-mediated inducibility of male-biased
isoforms of cytochrome P450 was better
when cultures were derived from male
rats but not female rats. Taken together,
these data show the retention of sex bias
in cells in culture in the absence of any
direct steroid hormone additions. Waxman and Holloway (27) suggested that
this results from lasting effects of sex-biased chromatin remodeling in female
versus male cells.
Tenth, we emphasize that in the hypothesis outlined in Figure 1, we specifically combine both central neuroendocrine mechanisms with peripheral
tissue–level mechanisms in the pathogenesis of PH. For example, we clearly visualize that biologically activated MCTP
would directly affect pulmonary vascular
cells in the process of generating a PH
phenotype in male rats (64). The male
dominance in this model would derive
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from how the inactive MCT is converted
into the active MCTP through CYP3A enzymes, which are themselves upregulated
by the GH-STAT5 axis in a sex-biased
manner (27,70,71).
Eleventh, the male bias in disease
worsening in SSc-associated PH (11,12),
the lack of sex bias in schistosomiasis-associated PH (13) and the small male bias
in development of HIV-associated PH
(14) are likely due to localized pulmonary vascular-level activation of immune processes that include STAT5 activation (112–117).
STAT5a/b AND BCL6 IN VASCULAR
CELLS
STAT5a/b transcription factors are activated by Tyr phosphorylation by a range
of cytokines and growth factors including
interleukin (IL)-2, GM-CSF, IL-6, PDGF
and erythropoietin and participate in mediating Th2 responses (112). Waxman and
colleagues have identified BCL6, a master
transcriptional repressor affecting hundreds of genes, as a male-biased downstream effector of PY-STAT5 activation
(27,46–48). Our attention to BCL6 resulted
from (a) the knowledge that this master
regulator is involved in regulating B-cell
development and function and follicular
T helper cell function, and its genetic
deletion results in a hypercytokine production state, which includes pulmonary
vasculitis (118–120); (b) that STAT5a/b
and BCL6 are expressed ubiquitously in
different tissues and function, respectively, as master transcription activator
and master transcription repressor (27);
and (c) that several investigators have
proposed that PH pathogenesis involves a
component of localized pulmonary vascular inflammation (121–123). Thus, a reduction in BCL6 in cells in obliterative lesions
of PH (Figure 7) would enhance localized
proinflammatory cytokine production
(plus changes in expression of hundreds
of additional genes) (27,118,119). We
would expect the conditional localized
deletion of BCL6 in vascular smooth muscle cells in mice to also lead to an abrogation of sex bias in the chronic hypoxia
model of PH (Figure 1).

It has been established over the last 2
decades that the expression levels of
STAT5a and STAT5b in different adult
tissues are approximately equal in males
and females in rodents and humans
(27,28,112). Thus, the sex-specific differences between males and females in
STAT5 biology in adult tissues is in
terms of patterns of activation of the
transcription factor (PY-STAT5) and not
regulation of expression per se. In contrast, BCL6 expression, mediated by PYSTAT5 itself, is male-biased (27,46,47).
STAT5 has also been identified as a
tumor suppressor (118,119). In terms of
clinical outcome, a reduction in STAT5a
expression is associated with worse
prognosis in breast and prostate cancer
(124,125). Thus, a reduction in STAT5
levels corresponds to increased cell proliferation and tumorigenesis. Reduced
STAT5 content (nonphosphorylated and
phosphorylated) in cells in obliterative
lesions in PH (28) (Figure 7) is consistent
with this view of a loss of a tumor suppressor in a proliferative lesion.
We posit that sex bias in PH pathogenesis would be generated early in the disease process by the patterned activation
of intact levels of STAT5a/b and BCL6
(Figure 1). This result would transition in
late-stage disease to an overt reduction in
STAT5a/b, PY-STAT5 and BCL6 levels in
lesions in both female and male patients.
This loss of STAT5a/b, PY-STAT5 and
BCL6 in late-stage disease would set the
stage for enhanced cell proliferation, cell
hypertrophy and increased localized cytokine production and localized inflammation, and thus arterial remodeling.
What regulates the level of expression
of STAT5 in vascular tissues? There is an
increase in STAT5a and STAT5b expression in mammary epithelium in the female at puberty (126). However, changes
in expression of STAT5a/b in vascular
tissues at puberty and its sex dependence have not been investigated. Some
mechanisms that regulate STAT5a/b expression levels and function include
BCL6 itself (as repressor), microRNA 222
(miR222), transforming growth factor
(TGF)-β and BMP/Smad signaling and

the HIV negative regulatory factor (nef)
protein (reviewed in 28). At this time,
what downregulates STAT5a/b levels in
SMCs in obliterative IPAH lesions in
late-stage disease in both men and
women is not known.
SEX-BIAS EFFECTS DEPEND ON THE SUM
OF A PLETHORA OF CHANGES IN GENE
EXPRESSION
It is clear from the work of Waxman
and colleagues that sex bias in hepatocyte
biology due to the operation of the GHSTAT5-BCL6 axis is the net result of
changes that include the altered expression of at least 500–1,000 genes (Figure 1)
(27). We anticipate that a similar large
pool of gene expression changes will underlie the sex-bias phenotypes observed
in PH. We anticipate that a different spectrum of changes will be observed in different vascular cell types (smooth muscle,
endothelial cells) under different PH situations. We emphasize that the GH-STAT5BCL6 axis regulates target genes through
multiple dynamical parameters (GH
pulse height, pulse frequency, interpulse
intervals, interpulse levels, speed of onset
of PY-STAT5 activation, termination of
PY-STAT5 activation, rate of decrease in
nuclear PY-STAT5 levels, activation and
repression of a cascade of additional master transcription factors and repressors,
sex-biased chromatin remodeling of the
hundreds of different target genes differently in different cell types) (27), such that
at the present time, it would be premature
to single out one or more mediators. We
project that these downstream events will
include altered expression of multiple mediators of intracellular regulatory pathways (transcription, translation and intracellular trafficking) as well as extracellular
communication (cytokines and growth
factors) acting in concert to generate the
overall sex-biased phenotype. As to the
question to what extent does PY-STAT5
activation protect against PH or cause PH,
the answers would be “both” and “neither,” depending upon the species, sex
and PH circumstance. Despite these complexities, the purpose of this essay is to
draw attention to two specific entities
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(GH and STAT5) in establishing a functional connection between the hypothalamus on the one hand and pulmonary vascular tissues on the other hand as a
mechanism for generating sex bias in the
latter. Upstream of GH would be the multifactorial sex-bias mechanisms that impinge on the hypothalamus, and downstream of STAT5 in pulmonary vascular
cells would be hundreds of “pattern” responsive genes that together comprise the
sex-biased disease process.
CONCLUSION
Fifty years ago, Frantz and Rabkin
(127) pointed out that the fasting ambulatory levels of plasma GH in women
were markedly higher than levels in
men. Physical activity enhanced GH levels, particularly in women. These authors
also reported that men administered estrogen (diethylstilbestrol) showed the
“female pattern” of ambulatory GH (that
is, marked elevation of GH levels) and
postulated that this was due to the effect
of estrogen to enhance “pituitary sensitivity, or that of higher centers” to “physical activity and possibly other stimuli”
(127). Today, the neuroendocrine-GHSTAT5 axis represents a novel way to
think about sex bias in the pathogenesis
of a vascular disease—pulmonary hypertension. This hypothesis connects the
hypothalamus/pituitary through wellestablished regulatory mechanisms to
sex-biased changes in gene expression in
pulmonary vascular tissues. It also provides a path toward explaining many of
the puzzlements observed in sex bias in
human PH and in rodent models of this
disease. The detailed elucidation of these
GH-STAT5–based molecular mechanisms
may lead to identification of novel targets for therapy and, perhaps more importantly, prophylaxis of this disease.
NOTE ADDED IN PROOF
Recently, Savai et al. (128) have drawn
attention to the reduction in expression
of the forkhead transcription factors
FoxO1, FoxO3 and BCL6 (and additional
“FoxO1 targets”) in SMCs in pulmonary
vascular lesions and in microdissected

vessels from patients with IPAH (both
sexes). FoxO1, FoxO3 and BCL6 were
also reduced in microdissected vessels
from male rats with PH in the hypoxiaSugen model, but only FoxO1 and BCL6
were reduced in the MCT male rat
model. These investigators did not investigate STAT5a/b expression. SMC-specific deletion of FoxO1 using the SM22Cre approach generated mice that
showed PH under normoxic conditions
and a more severe PH in response to hypoxia compared with wt mice (males and
females were pooled). Enhancing FoxO1
expression by administering FoxO1 adenovirus or paclitaxel reduced the severity of PH in the MCT rat and the hypoxia-Sugen/rat models. Savai et al.
(128) suggested that a pro-proliferative
and inflammatory state, generated by the
loss of FoxO1, BCL6, growth arrest and
DNA damage (GADD45) and other molecules, contributes to the development of
PH. However, these investigators did not
discuss the relationships between FoxO
transcription factors, BCL6 and the GHSTAT5 axis. Our data showing the loss of
BCL6 in cells in obliterative lesions in
both male and female late-stage IPAH
patients (Figure 7) confirm the loss of
BCL6 observed by Savai et al. in IPAH
(128). However, there is an already
known interplay between STAT5a/b,
BCL6, FoxO1 and FoxO3. Both the FoxO1
and FoxO3 promoters have STAT5-binding sites (128) (Qiagen CHiP database).
FoxO1 is repressed by STAT5 binding
(129). The GH-STAT5 axis is known to
functionally repress a large cluster of
genes targeted for activation by FoxO1
(130). Activated STAT5 upregulates expression of miR-182, which targets
FoxO1 mRNA for degradation (131). We
note that Waxman and colleagues previously showed that expression in murine
hepatocytes of BCL6 is male-biased and
GH-STAT5–dependent and that expression of various forkhead transcription
factors is also sex-biased in a STAT5dependent manner (27,41–48).
In recent years, several investigators
suggested that insulin resistance phenotypes, obesity and metabolic dysfunction
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contribute to pathogenesis of PH in humans and in animal models (132–137). As
examples, male mice with ApoE–/– deletion but not female mice developed PH
(134), and there was an increased prevalence of markers of insulin resistance
phenotype in female patients with PH
(135,136). Remarkably, it has been known
for >5 decades that insulin potently affects the hypothalamic-pituitary-GH axis,
including in the context of diet and obesity, and that this axis is dysfunctional in
insulin resistance (74,127,138–142). Indeed, today, the GH secretion response in
patients to administered insulin is taken
to be a gold standard to evaluate the integrity of these neuroendocrine mechanisms (138–142), and the relationships
(typically inverse) between insulin resistance and GH levels have been studied
extensively (74,140,142). Nevertheless,
even though the relationships between
the GH axis, estrogen administration, insulin resistance and sex-biased obesity
phenotypes are well established
(74,127,138–142), to date, the literature
in the area of insulin resistance, obesity
and PH pathogenesis (132–135) lacks consideration of any of these GH-anchored
neuroendocrine mechanisms.
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